ColoSense
FDA-approved qualitative stool RNA and occult-hemoglobin colorectal cancer screening test for average-risk adults age 45 years or older.
- Developer
- Geneoscopy
- Intended use
- Screening
- Cancer scope
- Colorectal cancer
- Specimen
- Stool
- Molecular modality
- Protein, RNA expression
- Current version
- Current ColoSense commercial lineage offered nationally via Labcorp as of 2026-09
- Evidence context
- 1 structured studies · 5 indexed performance results · 14 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.